Top Markets
#1 Islamic Coin Islamic Coin +151.47%
#2 DOVU DOVU +48.81%
#3 Black Phoenix Black Phoenix +34.68%
#4 Velvet Velvet +29.04%
#5 Cross Cross +22.45%
#6 Akedo Akedo +17.41%
#7 DoubleZero DoubleZero +14.34%
#8 Cap Cap +11.68%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.22%
#10 HOME HOME +10.23%
Coin of the day
Islamic Coin Islamic Coin
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Oxurion N.V. Oxurion N.V.

Oxurion N.V.

OXUR
Rang in aandelen #39567
Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a... Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a biopharmaceutical firm focused on researching, developing, and bringing to market treatments for various ocular conditions worldwide. Its primary commercialized offering is JETREA, a medication used to address vitreomacular adhesion and vitreomacular traction. The company's development pipeline includes THR-149, a plasma kallikrein inhibitor currently undergoing Phase II clinical trials for diabetic macular edema (DME), and THR-687, an integrin antagonist also in Phase II trials for DME. Oxurion has forged strategic partnerships with Bicycle Therapeutics, INC Research, and Galapagos NV. The organization was formerly known as ThromboGenics NV before officially changing its name to Oxurion NV in September 2018.
Aandeelprijs
$0.003084
Marktkapitalisatie
$434.03K
Verandering (1 dag)
-7.14%
Verandering (1 jaar)
-89.24%
Land
BE
Handel Oxurion N.V. (OXUR)

Categorie

Healthcare
Winst voor Oxurion N.V. (OXUR)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Oxurion N.V. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Oxurion N.V. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE